- Home
- HOPE vs VCEL Comparison
HOPE vs VCEL Comparison
Compare HOPE & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HOPE | VCEL |
|---|---|---|
| Founded | 1986 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2000 | 1996 |
Fundamental Metrics
Financial Performance| Metric | HOPE | VCEL |
|---|---|---|
| Price | $10.99 | $32.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $13.75 | ★ $58.50 |
| AVG Volume (30 Days) | ★ 706.7K | 468.7K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 0.49 | 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | $38.10 | $19.09 |
| Revenue Next Year | $10.98 | $17.96 |
| P/E Ratio | ★ $22.04 | $101.67 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $8.83 | $29.24 |
| 52 Week High | $12.79 | $48.75 |
Technical Indicators
Market Signals| Indicator | HOPE | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 34.53 | 40.26 |
| Support Level | $10.72 | $29.59 |
| Resistance Level | $11.21 | $38.48 |
| Average True Range (ATR) | 0.30 | 1.40 |
| MACD | -0.07 | -0.27 |
| Stochastic Oscillator | 22.78 | 28.70 |
Price Performance
Historical ComparisonAbout HOPE Hope Bancorp Inc.
Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services, and other banking services.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.